NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors - Seite 3

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

For further information, please contact:

NeoGenomics, Inc.

William B. Bonello
Chief Financial Officer
T: 239.690.4238
M: 239.284.4314
[e-mail]

SOURCE: NeoGenomics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/724435/NeoGenomics-Appoints-David-Perez-Ind ...


The Neogenomics Stock at the time of publication of the news with a fall of -0,68 % to 7,334EUR on Tradegate stock exchange (04. November 2022, 22:26 Uhr).